Physician profile
Sunil Gupta
NPI 1508979311
$5,035.23
in general payments reported to CMS, 2019-2025
42 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $367 · 2021: $13.73 · 2022: $768 · 2023: $511 · 2024: $880 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055 · Travel and Lodging: $17.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.92 |
| Travel and Lodging | $17.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $557.74 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $440.68 | 2022-2025 | Onpattro, Amvuttra |
| Pfizer INC. | $410.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $391.92 | 2019-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $346.27 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $304.00 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $236.56 | 2025 | Opsumit, Uptravi |
| Abbott Laboratories | $221.16 | 2022-2025 | Assurity |
| Cvrx, INC. | $212.85 | 2023-2025 | Barostim Neo System |
| Recor Medical INC | $194.02 | 2024 | Paradise Renal Denervation System |
| Amgen INC. | $189.45 | 2019-2020 | |
| Biotronik INC. | $164.56 | 2021-2022 | |
| Heartflow, INC. | $132.03 | 2025 | |
| Medtronic, INC. | $113.51 | 2022-2025 | Micra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.65 | 2019-2023 | Jardiance |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $100.59 | 2019-2024 | |
| Edwards Lifesciences Corporation | $99.17 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $94.24 | 2022-2025 | General - Crm_crm, Varithena Administration Pack |
| Merck Sharp & Dohme LLC | $81.45 | 2024-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $74.92 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $70.67 | 2019-2025 | |
| Penumbra, INC. | $50.04 | 2022-2023 | Indigo System |
| Genentech USA, INC. | $43.72 | 2022 | |
| Astellas Pharma US INC | $38.00 | 2019-2020 | |
| Scpharmaceuticals INC. | $37.77 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $29.59 | 2019 | |
| Infobionic, INC | $26.98 | 2024 | Mome Device |
| Kite Pharma, INC. | $26.51 | 2025 | Yescarta |
| Kestra Medical Technology Services, INC. | $24.58 | 2024 | Assure Wcd |
| Kerecis Limited | $23.04 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Cardiva Medical, INC. | $22.20 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Kiniksa Pharmaceuticals International, Plc | $22.02 | 2024 | Arcalyst |
| Philips North America LLC | $20.10 | 2024 | (Ck4) Mcot |
| Regeneron Healthcare Solutions, INC. | $19.63 | 2019 | |
| Daiichi Sankyo INC. | $18.37 | 2023 | Injectafer |
| Amarin Pharma, INC. | $16.98 | 2020 | |
| Medicomp INC | $16.96 | 2019 | |
| Esperion Therapeutics, INC. | $15.63 | 2025 | Nexletol |
| Baxter Healthcare | $14.95 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Convatec INC. | $14.21 | 2025 | |
| Glaxosmithkline, LLC. | $13.87 | 2025 | Arexvy, Shingrix |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.